NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS (continued)

FOR THE YEAR ENDED 30 JUNE 2018

17. Employment benefit liability (continued)

The provision for management incentive bonuses was payable at the end of October 2017 and May 2018, whilst the remaining provision for staff is payable at the end of December 2018 to staff as part of a salary restructuring arrangement based on their cost to Company. The leave pay provisions are primarily in respect of leave pay to be settled in the next financial year.

18. Revenue

	Group		Company	
	June 2018 R'000	June 2017 R'000	June 2018 R'000	June 2017 R'000
Revenue from sale of goods	**1 241 769**	1 069 435	**–**	–
Administration fees	**1 411 297**	1 385 844	**–**	–
Health risk management fees	**1 117 970**	929 411	**–**	–
Management fees	**2 550**	1 869	**–**	–
IT revenue and other	**428 921**	398 142	**50**	50
Healthcare insurance	**10 198**	–	**–**	–
Revenue from performance of services	**2 970 936**	2 715 266	**50**	50
Total revenue	**4 212 705**	3 784 701	**50**	50

19. Cost of pharmaceutical products and finished goods

	Group		Company	
	June 2018 R'000	June 2017 R'000	June 2018 R'000	June 2017 R'000
Opening inventory	**73 376**	72 310	**–**	–
Purchases	**934 790**	837 800	**–**	–
Closing inventory	**(83 532)**	(73 376)	**–**	–
	924 634	836 734	**–**	–